Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas
| Autor: | V. Wagner, Wolfgang Stremmel, H Näher, Jochen Rudi |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Pancreatic disease endocrine system diseases Enzyme-Linked Immunosorbent Assay Gastroenterology Internal medicine Biomarkers Tumor medicine Carcinoma Humans In patient Gastrointestinal cancer Aged Gastrointestinal Neoplasms Tumor marker Extracellular Matrix Proteins Hematology business.industry Gallbladder Melanoma S100 Proteins General Medicine Middle Aged Prognosis medicine.disease digestive system diseases Neoplasm Proteins medicine.anatomical_structure Oncology Disease Progression Female business |
| Zdroj: | Medical Oncology. 17:35-38 |
| ISSN: | 1559-131X 1357-0560 |
| DOI: | 10.1007/bf02826214 |
| Popis: | Serum levels of melanoma inhibiting activity (MIA) and S100, both markers in malignant melanoma, are increased only in few patients with non-melanocytic tumors. We examined a series of serum samples from patients with colorectal (CRC) (N=56), gastric (GC) (N=43), pancreatic (PC) (N=29), hepatocellular (HCC) (N=30), cholangiocellular and gallbladder carcinoma (CCC) (N=18). MIA and S100 were measured by commercially available assays. Positive serum levels for MIA and S100 were found in 16.1% and 5.4% of the patients with CRC, 11.6% and 9.3% with GC, 34.5% and 13.8% with PC, 0% and 30% with HCC and 16.7% with CCC, respectively. All patients with sera positive for either MIA or S100 suffered from advanced tumors and received palliative treatment. Elevated serum levels of MIA and S100 are frequent in patients with gastrointestinal cancer. Further investigation is warranted to define the role of MIA or S100 seropositivity in gastrointestinal cancer with regard to follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink